Pepe Alcami

List of Publications by Year
in descending order

209	8,178	36303	66911
papers	citations	51 h-index	78 g-index

230	230	230	11498
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. PLoS Pathogens, 2022, 18, e1010171.	4.7	18
2	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Reports, 2022, 38, 110235.	6.4	35
3	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	3.4	10
4	Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients. Frontiers in Virology, 2022, 2, .	1.4	0
5	Elevated Î±-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control. Frontiers in Immunology, 2022, 13, 822272.	4.8	4
6	Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection. Journal of Clinical Medicine, 2022, 11, 2137.	2.4	2
7	Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development (Cambridge), 2022, 149, .	2.5	12
8	Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection. Frontiers in Cell and Developmental Biology, 2022, 10, .	3.7	1
9	The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans. IScience, 2022, , 104409.	4.1	4
10	Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19. Journal of Clinical Medicine, 2022, 11, 2803.	2.4	5
11	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. EClinicalMedicine, 2022, 50, 101529.	7.1	3
12	Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study. EClinicalMedicine, 2022, 51, 101542.	7.1	5
13	A Founder Effect Led Early SARS-CoV-2 Transmission in Spain. Journal of Virology, 2021, 95, .	3.4	55
14	Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis. PLoS Pathogens, 2021, 17, e1009526.	4.7	10
15	Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. Frontiers in Immunology, 2021, 12, 665329.	4.8	26
16	Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV,the, 2021, 8, e294-e305.	4.7	129
17	Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine. Vaccines, 2021, 9, 694.	4.4	8
18	Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals. Vaccines, 2021, 9, 799.	4.4	3

#	Article	IF	Citations
19	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	13.7	316
20	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. Frontiers in Immunology, 2021, 12, 730691.	4.8	2
21	A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Journal of Clinical Investigation, 2021, 131, .	8.2	100
22	Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU. Frontiers in Immunology, 2021, 12, 742631.	4.8	23
23	Withanolide-Type Steroids from Physalis nicandroides Inhibit HIV Transcription. Journal of Natural Products, 2021, 84, 2717-2726.	3.0	4
24	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochemical Pharmacology, 2021, 192, 114666.	4.4	8
25	Extensive GJD2 Expression in the Song Motor Pathway Reveals the Extent of Electrical Synapses in the Songbird Brain. Biology, 2021, 10, 1099.	2.8	2
26	Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Journal of Clinical Medicine, 2021, 10, 42.	2.4	13
27	Association of a single nucleotide polymorphism in the ubxn6 gene with long-term non-progression phenotype in HIV-positive individuals. Clinical Microbiology and Infection, 2020, 26, 107-114.	6.0	3
28	Dasatinib protects humanized mice from acute HIV-1 infection. Biochemical Pharmacology, 2020, 174, 113625.	4.4	13
29	Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochemical Pharmacology, 2020, 182, 114203.	4.4	9
30	Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection. Journal of Clinical Medicine, 2020, 9, 2452.	2.4	11
31	Ethanolic extract of Artemisia campestris subsp. glutinosa (Besser) Batt. inhibits HIVâ€“1 replication in vitro through the activity of terpenes and flavonoids on viral entry and NFâ€“ÎºB pathway. Journal of Ethnopharmacology, 2020, 263, 113163.	4.1	17
32	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	30.7	96
33	Nucleic acid recognition and antiviral activity of 1,4-substituted terphenyl compounds mimicking all faces of the HIV-1 Rev protein positively-charged Î±-helix. Scientific Reports, 2020, 10, 7190.	3.3	9
34	Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ÄŸ Mediation. Journal of Clinical Medicine, 2020, 9, 959.	2.4	4
35	4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat. Biochemical Pharmacology, 2020, 177, 113937.	4.4	10
36	PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients. Journal of Clinical Investigation, 2020, 130, 2872-2887.	8.2	24

#	Article	IF	Citations
37	Axonal Computations. Frontiers in Cellular Neuroscience, 2019, 13, 413.	3.7	25
38	Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients. PLoS ONE, 2019, 14, e0220459.	2.5	10
39	The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS Pathogens, 2019, 15, e1007958.	4.7	22
40	Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Current HIV/AIDS Reports, 2019, 16, 414-422.	3.1	5
41	Transcriptome Sequencing of Peripheral Blood Mononuclear Cells from Elite Controller-Long Term Non Progressors. Scientific Reports, 2019, 9, 14265.	3.3	29
42	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nature Communications, 2019, 10, 2355.	12.8	116
43	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. Scientific Reports, 2019, 9, 5606.	3.3	22
44	Beyond plasticity: the dynamic impact of electrical synapses on neural circuits. Nature Reviews Neuroscience, 2019, 20, 253-271.	10.2	107
45	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. Journal of Microbiology, Immunology and Infection, 2019, 52, 667-671.	3.1	14
46	Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. Journal of Virology, 2019, 93, .	3.4	26
47	Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Blood, 2019, 134, 191-191.	1.4	2
48	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. BMC Medicine, 2018, 16, 30.	5.5	19
49	Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc. Journal of Virology, 2018, 92, .	3.4	2
50	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	58
51	SituaciÃ³n de la investigaciÃ³n sobre el VIH en EspaÃ±a. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 26-30.	0.5	3
52	CCR5 structural plasticity shapes HIV-1 phenotypic properties. PLoS Pathogens, 2018, 14, e1007432.	4.7	27
53	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Biochemical Pharmacology, 2018, 156, 248-264.	4.4	14
54	A small-molecule inhibitor of HIV-1 Rev function detected by a diversity screen based on RRE-Rev interference. Biochemical Pharmacology, 2018, 156, 68-77.	4.4	19

#	Article	IF	Citations
55	Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets. Frontiers in Pharmacology, 2018, 9, 358.	3.5	6
56	Electrical Synapses Enhance and Accelerate Interneuron Recruitment in Response to Coincident and Sequential Excitation. Frontiers in Cellular Neuroscience, 2018, 12, 156.	3.7	15
57	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	2.5	24
58	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clinical Infectious Diseases, 2017, 64, ciw833.	5.8	28
59	5-Hydroxytyrosol inhibits HIV-1 replication in primary cells of the lower and upper female reproductive tract. Antiviral Research, 2017, 142, 16-20.	4.1	6
60	Different Expression of Interferon-Stimulated Genes in Response to HIV-1 Infection in Dendritic Cells Based on Their Maturation State. Journal of Virology, 2017, 91, .	3.4	6
61	The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Scientific Reports, 2017, 7, 2385.	3.3	38
62	Potential role of tyrosine kinase inhibitors during primary HIV-1 infection. Expert Review of Anti-Infective Therapy, 2017, 15, 421-423.	4.4	4
63	Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. Expert Opinion on Drug Safety, 2017, 16, 547-559.	2.4	12
64	MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter. Nucleic Acids Research, 2017, 45, 9960-9975.	14.5	13
65	Environmentally Friendly Procedure Based on Supercritical Fluid Chromatography and Tandem Mass Spectrometry Molecular Networking for the Discovery of Potent Antiviral Compounds from Euphorbia semiperfoliata. Journal of Natural Products, 2017, 80, 2620-2629.	3.0	51
66	Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients. Virology, 2017, 500, 247-258.	2.4	2
67	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. Journal of Virus Eradication, 2017, 3, 236-241.	0.5	0
68	Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-Î²B Pathways. Molecules, 2017, 22, 321.	3.8	7
69	Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells. PLoS ONE, 2017, 12, e0185677.	2.5	21
70	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. PLoS ONE, 2017, 12, e0186602.	2.5	20
71	Somatostatin-positive interneurons in the dentate gyrus of mice provide local- and long-range septal synaptic inhibition. ELife, 2017, 6, .	6.0	73
72	Converging roads: the latest science from the 2017 IAS HIV Cure and Cancer Forum. Journal of Virus Eradication, 2017, 3, 236-241.	0.5	0

#	Article	IF	Citations
73	PKCÎ¸ and HIV-1 Transcriptional Regulator Tat Co-exist at the LTR Promoter in CD4+ T Cells. Frontiers in Immunology, 2016, 7, 69.	4.8	9
74	Rate and predictors of progression in elite and viremic HIV-1 controllers. Aids, 2016, 30, 1209-1220.	2.2	69
75	Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. Aids, 2016, 30, 1015-1025.	2.2	17
76	IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle. Cell Reports, 2016, 14, 2100-2107.	6.4	64
77	Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins. Journal of Virological Methods, 2016, 236, 184-195.	2.1	6
78	Hydroxytyrosol. Aids, 2016, 30, 2767-2776.	2.2	23
79	Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. Journal of Virology, 2016, 90, 5231-5245.	3.4	31
80	Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochemical Pharmacology, 2016, 106, 30-45.	4.4	50
81	Bioavailable inhibitors of HIV-1 RNA biogenesis identified through a Rev-based screen. Biochemical Pharmacology, 2016, 107, 14-28.	4.4	25
82	Analysis of Non-AIDS-Defining Events in HIV Controllers. Clinical Infectious Diseases, 2016, 62, 1304-1309.	5.8	34
83	An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies. PLoS ONE, 2016, 11, e0166902.	2.5	7
84	Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication. Retrovirology, 2015, 12, 78.	2.0	27
85	A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. Retrovirology, 2015, 12, 50.	2.0	27
86	Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing. PLoS ONE, 2015, 10, e0139812.	2.5	10
87	Involvement of the Rac1-IRSp53-Wave2-Arp2/3 Signaling Pathway in HIV-1 Gag Particle Release in CD4 T Cells. Journal of Virology, 2015, 89, 8162-8181.	3.4	34
88	Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina. Journal of Natural Products, 2015, 78, 1045-1055.	3.0	47
89	Negatively Charged Glyconanoparticles Modulate and Stabilize the Secondary Structures of a gp120 V3 Loop Peptide: Toward Fully Synthetic HIV Vaccine Candidates. Bioconjugate Chemistry, 2015, 26, 755-765.	3.6	30
90	Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription. Biochemical Pharmacology, 2015, 94, 241-256.	4.4	22

#	Article	IF	Citations
91	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
92	Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. Pharmacogenomics, 2014, 15, 569-572.	1.3	4
93	Antiviral Activity of 5-Hydroxytyrosol, a Microbicidal Candidate against HIV-1 Transmission. AIDS Research and Human Retroviruses, 2014, 30, A240-A240.	1.1	0
94	Candidate Microbicide 5-hydroxytyrosol (5-HT) Inhibits Productive R5 HIV-1 Infection of Human Cervical Tissue Explants (CTE). AIDS Research and Human Retroviruses, 2014, 30, A264-A264.	1.1	0
95	Combinations of Entry and Reverse Transcriptase Inhibitors as Candidate Microbicides. AIDS Research and Human Retroviruses, 2014, 30, A213-A213.	1.1	0
96	Mucosal Tissue Explants as Surrogates for In Vivo Efficacy of Microbicides. AIDS Research and Human Retroviruses, 2014, 30, A60-A60.	1.1	0
97	Preclinical Evaluation of Multi-targeting Antiretroviral Drug Based-combinations as Candidate Microbicides. AIDS Research and Human Retroviruses, 2014, 30, A262-A262.	1.1	0
98	Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication. Retrovirology, 2013, 10, 124.	2.0	12
99	InnenrÃ¼cktitelbild: Structure-Based Design of an RNA-Bindingp-Terphenylene Scaffold that Inhibits HIV-1 Rev Protein Function (Angew. Chem. 50/2013). Angewandte Chemie, 2013, 125, 13719-13719.	2.0	0
100	Immune Activation Promotes Evolutionary Conservation of T-Cell Epitopes in HIV-1. PLoS Biology, 2013, 11, e1001523.	5.6	16
101	The Presence of HIV-1 Tat Protein Second Exon Delays Fas Protein-mediated Apoptosis in CD4+ T Lymphocytes. Journal of Biological Chemistry, 2013, 288, 7626-7644.	3.4	47
102	HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9475-9480.	7.1	61
103	Determination of HIV tropism and its use in the clinical practice. Expert Review of Anti-Infective Therapy, 2013, 11, 1291-1302.	4.4	12
104	Estimating functional connectivity in an electrically coupled interneuron network. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4798-E4807.	7.1	44
105	Structureâ€Based Design of an RNAâ€Binding pâ€Terphenylene Scaffold that Inhibits HIVâ€1 Rev Protein Function. Angewandte Chemie - International Edition, 2013, 52, 13405-13409.	13.8	28
106	Use of RT-Defective HIV Virions: New Tool to Evaluate Specific Response in Chronic Asymptomatic HIV-Infected Individuals. PLoS ONE, 2013, 8, e58927.	2.5	9
107	Measuring the Firing Rate of High-Resistance Neurons with Cell-Attached Recording. Journal of Neuroscience, 2012, 32, 3118-3130.	3.6	57
108	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68.	2.0	7

#	Article	IF	Citations
109	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. PLoS ONE, 2012, 7, e36438.	2.5	63
110	Generation and Characterization of a Defective HIV-1 Virus as an Immunogen for a Therapeutic Vaccine. PLoS ONE, 2012, 7, e48848.	2.5	10
111	3-Phenylcoumarins as Inhibitors of HIV-1 Replication. Molecules, 2012, 17, 9245-9257.	3.8	67
112	Olean-18-ene triterpenoids from Celastraceae species inhibit HIV replication targeting NF-kB and Sp1 dependent transcription. European Journal of Medicinal Chemistry, 2012, 52, 295-303.	5.5	33
113	Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression. PLoS ONE, 2012, 7, e50204.	2.5	10
114	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. AIDS Reviews, 2012, 14, 208-17.	1.0	35
115	CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. Cytokine, 2011, 53, 184-190.	3.2	44
116	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
117	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine, 2011, 29, 8309-8316.	3.8	70
118	Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1365-1382.	3.3	8
119	Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5). Journal of Biological Chemistry, 2011, 286, 33409-33421.	3.4	101
120	New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection. Journal of Biological Chemistry, 2011, 286, 4978-4990.	3.4	73
121	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Journal of Virology, 2011, 85, 5804-5813.	3.4	37
122	Protein Kinase CÎ¸ Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+ T Lymphocytes*. Journal of Biological Chemistry, 2011, 286, 27363-27377.	3.4	29
123	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 473-478.	4.0	105
124	Hot Immunological Topics in HIV Infection. Journal of AIDS & Clinical Research, 2011, 02, .	0.5	9
125	Broadly Neutralizing Antibodies and their Significance for HIV-1 Vaccines. Current HIV Research, 2010, 8, 602-612.	0.5	12
126	Ellagitannins from Tuberaria lignosa as entry inhibitors of HIV. Phytomedicine, 2010, 17, 69-74.	5.3	23

#	Article	IF	Citations
127	Quinoline-based compounds as modulators of HIV transcription through NF-Î¹B and Sp1 inhibition. Antiviral Research, 2010, 87, 338-344.	4.1	59
128	Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. Antiviral Research, 2010, 88, 152-159.	4.1	11
129	Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2718-2721.	2.2	135
130	Molecular mechanisms involved in HIV latency and implications for HIV treatment and eradication. Retrovirology, 2010, 7, .	2.0	1
131	Allosteric regulation by non peptidic, low molecular weight compounds of CCR5 coupling to g-proteins and interaction with Gp120 - consequences on inhibition of R5 HIV-1 infection. Retrovirology, 2010, 7, .	2.0	0
132	Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Research, 2010, 38, 3287-3307.	14.5	55
133	SDF-1/CXCL12 Production by Mature Dendritic Cells Inhibits the Propagation of X4-Tropic HIV-1 Isolates at the Dendritic Cell-T-Cell Infectious Synapse. Journal of Virology, 2010, 84, 4341-4351.	3.4	25
134	The Carboxyl-terminal Domain of Connexin43 Is a Negative Modulator of Neuronal Differentiation. Journal of Biological Chemistry, 2010, 285, 11836-11845.	3.4	43
135	A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. Journal of Antimicrobial Chemotherapy, 2010, 65, 2493-2501.	3.0	35
136	c/EBPÎ² Is a Major Regulatory Element Driving Transcriptional Activation of the CXCL12 Promoter. Journal of Molecular Biology, 2010, 396, 463-472.	4.2	21
137	HIV-1 latency and eradication of long-term viral reservoirs. Discovery Medicine, 2010, 9, 185-91.	0.5	10
138	Dual role of host cell factors in HIV-1 replication: restriction and enhancement of the viral cycle. AIDS Reviews, 2010, 12, 103-12.	1.0	14
139	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. AIDS Reviews, 2010, 12, 135-48.	1.0	42
140	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. PLoS ONE, 2009, 4, e4505.	2.5	109
141	A novel factor distinct from E2F mediates C-MYC promoter activation through its E2F element during exit from quiescence. Carcinogenesis, 2009, 30, 440-448.	2.8	13
142	SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochemical Pharmacology, 2009, 77, 965-978.	4.4	54
143	Multivalent Mannoâ€Glyconanoparticles Inhibit DCâ€SIGNâ€Mediated HIVâ€1 Transâ€Infection of Human T Cells. ChemBioChem, 2009, 10, 1806-1809.	2.6	117
144	In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. Journal of Medical Virology, 2009, 81, 211-216.	5.0	5

#	Article	IF	Citations
145	Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature Reviews Microbiology, 2009, 7, 798-812.	28.6	235
146	P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group. Retrovirology, 2009, 6, .	2.0	1
147	Modifications in host cell structure and functions mediated by Tat intracellular expression are greatly dependent on the second exon. Retrovirology, 2009, 6, .	2.0	0
148	Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression. Current HIV Research, 2009, 7, 384-389.	0.5	20
149	Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics, 2008, 8, 852-873.	2.2	31
150	A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV Medicine, 2008, 9, 160-171.	2.2	10
151	Guatemalan plants extracts as virucides against HIV-1 infection. Phytomedicine, 2008, 15, 520-524.	5.3	20
152	Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits IÎºBÎ± and enhances HIV-1 replication in human T lymphocytes. Retrovirology, 2008, 5, 109.	2.0	25
153	Optimal use of maraviroc in clinical practice. Aids, 2008, 22, 2231-2240.	2.2	33
154	Basal shuttle of NF-ÎºB/IÎºBÎ± in resting T lymphocytes regulates HIV-1 LTR dependent expression. Retrovirology, 2007, 4, 56.	2.0	34
155	A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. Journal of Medical Virology, 2007, 79, 127-137.	5.0	70
156	Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. Virus Genes, 2007, 34, 111-116.	1.6	17
157	Modifications in the human Tâ€…cell proteome induced by intracellular HIV-1 Tat protein expression. Proteomics, 2006, 6, S63-S73.	2.2	66
158	Anti-HIV activity of stilbene-related heterocyclic compounds. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4075-4079.	2.2	47
159	Fas activation of a proinflammatory program in rheumatoid synoviocytes and its regulation by FLIP and caspase 8 signaling. Arthritis and Rheumatism, 2006, 54, 1473-1481.	6.7	25
160	4-Phenylcoumarins as HIV transcription inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4447-4450.	2.2	69
161	Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-ÎºB pathway. Antiviral Research, 2005, 66, 137-145.	4.1	57
162	Association between stromal cell-derived factor 1 chemokine gene variant and radiographic progression of rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 354-356.	6.7	26

#	Article	IF	Citations
163	SituaciÃ³n actual en el desarrollo de una vacuna preventiva frente al VIH. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2005, 23, 5-14.	0.5	0
164	Therapeutic Immunization with Dendritic Cells Loaded with Heatâ€inactivated Autologous HIVâ€1 in Patients with Chronic HIVâ€1 Infection. Journal of Infectious Diseases, 2005, 191, 1680-1685.	4.0	147
165	Functional Characterization of SDF-1 Proximal Promoter. Journal of Molecular Biology, 2005, 348, 43-62.	4.2	72
166	Effect of Mycophenolate Mofetil on Immune Response and Plasma and Lymphatic Tissue Viral Load During and After Interruption of Highly Active Antiretroviral Therapy for Patients With Chronic HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 823-830.	2.1	71
167	Imperatorin Inhibits HIV-1 Replication through an Sp1-dependent Pathway. Journal of Biological Chemistry, 2004, 279, 37349-37359.	3.4	115
168	TRAF Family Proteins Link PKR with NF-ÎºB Activation. Molecular and Cellular Biology, 2004, 24, 4502-4512.	2.3	147
169	Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors. Journal of Medical Virology, 2004, 73, 502-507.	5.0	3
170	Anti-HIV Activity of Some Synthetic Lignanolides and Intermediates.. ChemInform, 2004, 35, no.	0.0	0
171	Anti-HIV activity of some synthetic lignanolides and intermediates. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4483-4486.	2.2	14
172	Avances en la inmunopatologÃa de la infecciÃ³n por el VIH. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2004, 22, 486-496.	0.5	2
173	Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antiviral Therapy, 2004, 9, 545-54.	1.0	22
174	Prostratin Induces HIV Activation and Downregulates HIV Receptors in Peripheral Blood Lymphocytes. Antiviral Therapy, 2004, 9, 545-554.	1.0	43
175	G Protein-Dependent CCR5 Signaling Is Not Required for Efficient Infection of Primary T Lymphocytes and Macrophages by R5 Human Immunodeficiency Virus Type 1 Isolates. Journal of Virology, 2003, 77, 2550-2558.	3.4	61
176	Plasma Stromal Cellâ€“Derived Factor (SDF)â€1 Levels, SDF1â€3â€²A Genotype, and Expression of CXCR4 on T Lymphocytes: Their Impact on Resistance to Human Immunodeficiency Virus Type 1 Infection and Its Progression. Journal of Infectious Diseases, 2002, 186, 922-931.	4.0	110
177	Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma. Journal of Clinical Microbiology, 2002, 40, 1518-1521.	3.9	28
178	Screening of South American Plants against Human Immunodeficiency Virus: Preliminary Fractionation of Aqueous Extract from Baccharis trinervis.. Biological and Pharmaceutical Bulletin, 2002, 25, 1147-1150.	1.4	25
179	Screening of selected plant extracts for in vitro inhibitory activity on Human Immunodeficiency Virus. Phytotherapy Research, 2002, 16, 550-554.	5.8	34
180	Anti-HIV activity of medicinal plant extracts. Journal of Ethnopharmacology, 2001, 77, 113-116.	4.1	69

#	Article	IF	Citations
181	Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clinical and Experimental Immunology, 2001, 123, 36-41.	2.6	78
182	Hydrogen peroxide increases extracellular matrix mRNA through TGF-Î² in human mesangial cells. Kidney International, 2001, 59, 87-95.	5.2	196
183	Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis and Rheumatism, 2001, 44, 1382-1386.	6.7	97
184	The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-ÎºB activation. Oncogene, 2001, 20, 385-394.	5.9	64
185	The Hepatitis B Virus X Protein Induces HIV-1 Replication and Transcription in Synergy with T-cell Activation Signals. Journal of Biological Chemistry, 2001, 276, 35435-35443.	3.4	95
186	MC159L protein from the poxvirus molluscum contagiosum virus inhibits NF-ÎºB activation and apoptosis induced by PKR. Journal of General Virology, 2001, 82, 3027-3034.	2.9	43
187	Where does free infective HIV-1 rebound come from?. Aids, 2001, 15, 657.	2.2	2
188	Activation of NF-ÎºB by the dsRNA-dependent protein kinase, PKR involves the IÎºB kinase complex. Oncogene, 2000, 19, 1369-1378.	5.9	125
189	Membrane raft microdomains mediate lateral assemblies required for HIVâ€¡ infection. EMBO Reports, 2000, 1, 190-196.	4.5	335
190	CCR5 genotype and HIV-1 infection in perinatally-exposed infants. Journal of Infection, 1999, 38, 9-11.	3.3	10
191	Natural Human Antibodies Retrieved by Phage Display Libraries from Healthy Donors: Polyreactivity and Recognition of Human Immunodeficiency Virus Type 1 gp120 Epitopes. Scandinavian Journal of Immunology, 1999, 50, 270-279.	2.7	16
192	Expression of IÎºBÎ± in the nucleus of human peripheral blood T lymphocytes. Oncogene, 1999, 18, 1581-1588.	5.9	24
193	Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. European Journal of Immunology, 1998, 28, 3192-3204.	2.9	71
194	LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Virus Research, 1998, 57, 11-20.	2.2	27
195	Genomic organization and promoter characterization of human CXCR4 gene1. FEBS Letters, 1998, 426, 271-278.	2.8	107
196	In vitro selective elimination of HIV-infected cells from peripheral blood in AIDS patients by the immunotoxin DAB389CD4. Aids, 1998, 12, 859-863.	2.2	8
197	Reverse transcriptase-like activity in Trypanosoma cruzi. Acta Tropica, 1997, 63, 117-126.	2.0	6
198	The amino-terminal domain of the CCR2 chemokine receptor acts as coreceptor for HIV-1 infection.. Journal of Clinical Investigation, 1997, 100, 497-502.	8.2	101

#	Article	IF	Citations
199	Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. Journal of Virology, 1994, 68, 5730-5737.	3.4	146
200	Antagonistic modulation of human cytomegalovirus replication by transforming growth factor beta and basic fibroblastic growth factor. Journal of General Virology, 1993, 74, 269-274.	2.9	23
201	NF-kappa B-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7826-7830.	7.1	74
202	CD11b-bearing mononuclear leucocytes and IgA levels in the staging of human immunodeficiency virus infection. Experientia, 1992, 48, 402-404.	1.2	2
203	HIV enhancer activity perpetuated by NF-Î²B induction on infection of monocytes. Nature, 1991, 350, 709-712.	27.8	209
204	Induction of an endothelial cell growth factor by human cytomegalovirus infection of fibroblasts. Journal of General Virology, 1991, 72, 2765-2770.	2.9	50
205	Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7861-7865.	7.1	108
206	Constitutive expression of human immunodeficiency virus (HIV) nef protein in human astrocytes does not influence basal or induced HIV long terminal repeat activity. Journal of Virology, 1990, 64, 3059-3062.	3.4	66
207	An in Vivo Functional Immune System Lacking Polyclonal T-Cell Surface Expression of the CD3/Ti(WT31) Complex. Scandinavian Journal of Immunology, 1987, 26, 699-707.	2.7	19
208	INDOMETHACIN IN THE RELIEF OF AIDS SYMPTOMS. Lancet, The, 1986, 328, 570.	13.7	7
209	Omic Technologies in HIV: Searching Transcriptional Signatures Involved in Long-Term Non-Progressor and HIV Controller Phenotypes. Frontiers in Immunology, 0, 13, .	4.8	0